^
Association details:
| Biomarker: | NF2 deletion |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment
Published date:
12/15/2020
Excerpt:
Next-generation sequencing (NGS) was performed using tumor specimens collected from 178 Asian patients with metastatic melanoma receiving CPIs….NRAS mutations, TP53 mutations, and NF2 deletions were significantly associated with resistance to CPIs (P < 0.05).
DOI:
10.1016/j.esmoop.2020.100002
Source:
Title:
Molecular features for selecting Asian metastatic melanoma patients who benefit from check-point inhibitors.
Published date:
05/13/2020
Excerpt:
NRAS and TP53 mutation and NF2 deletion were significantly related to patients without the response to CPIs (p < 0.05). Meanwhile, MYC and RPS6KB1 amplification were found with those with the response (p < 0.05). The median progression free survival (PFS) to ICIS was 5.9 months (95% CI 3.8 - 8.05 months).
DOI:
10.1200/JCO.2020.38.15_suppl.e22011
